Coste del tratamiento farmacológico de los factores de riesgo cardiovascular en población diabética anciana según género (Estudio ESCADIANE)

Abstract

AimsTo study the cost of pharmacological treatment used for the control of cardiovascular risk factors in patients with type 2 diabetes mellitus (DM2)> 65 years and the prevalence of cardiovascular complications according to gender. DesignCross-sectional, observational, multicentric study. LocationNational study. ParticipantsPatients with diabetes mellitus 2> 65 years. Main measurementsprevalence of cardiovascular risk factors and their cost in patients with diabetes mellitus 2. ResultsWe studied 947 patients (53% females) with a mean age of 76.2±7.3 years. 14% had suffered acute myocardial infarction (17.8% men vs. 10.7% women, p=.001), 11.9% had stroke (13.7% men vs. 10.5% women; p=ns), 11.3% heart failure (10.9% men vs. 11.7% women, p=ns) and 9% peripheral arterial disease (12.1% men vs. 6.3% women; p=.001). Oral antidiabetic drugs accounted for the highest cost (414.76±210.18 € patient / year), mainly due to DPP-4 inhibitors (49.9% of the cost of antidiabetics), followed by basal insulin (29.95%) and without significant differences between gender. The annual expenditure of antihypertensive drugs per patient/year was higher in women than in men (86.80±32.84 € vs. 78.24 €±26.86, p=0.0001). The antiaggregants significantly lower in women (20.87±7.25 € vs. € 30.21±13.68, p=0.0001). ConclusionsAntidiabetic drugs represented the highest cost in controlling cardiovascular risk factors in diabetic patients> 65 years of age, followed by hypotensives, hypolipements and antiaggregants. Women had higher spending on anti-hypertensives and men on antiaggregants.The most frequent macrovascular complications in men were AMI, arrhythmias and stroke. There were only gender differences for infarction.